Artwork

Dr Neil Love에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Dr Neil Love 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

Ovarian Cancer | Oncology Today with Dr Neil Love: The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer

1:09:32
 
공유
 

Manage episode 282696802 series 1464352
Dr Neil Love에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Dr Neil Love 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Featuring an interview with Dr Shannon N Westin on the following topics:

  • Evolving role of PARP inhibition in the management of ovarian cancer (OC) (0:00)
  • Frequency and clinical significance of germline and somatic BRCA mutations and other genomic signatures that may predict benefit from PARP inhibition (3:46)
  • Pivotal Phase III trials of PARP inhibitors alone or in combination with bevacizumab as maintenance therapy for patients with newly diagnosed OC (8:51)
  • Approaches to overcoming PARP inhibitor resistance; PARP inhibitors in combination with immune checkpoint inhibitors (17:56)
  • Novel immune checkpoint inhibitor-based regimens under investigation in OC (25:15)
  • Case: A woman in her early 40s with newly diagnosed high-grade serous OC with a somatic BRCA mutation (28:03)
  • Integration of maintenance PARP inhibition alone or in combination with bevacizumab into the management of newly diagnosed OC (33:32)
  • Duration of PARP inhibitor maintenance therapy; clinical management of common treatment-associated side effects (38:19)
  • Case: A woman in her mid-60s with newly diagnosed Stage IV high-grade serous OC with evidence of genomic instability on her homologous recombination deficiency test (43:09)
  • Activity and tolerability of olaparib/bevacizumab as maintenance therapy (51:14)
  • Case: A woman in her early 50s with newly diagnosed Stage IV homologous recombination-proficient OC (58:53)

CME information and select publications

  continue reading

1296 에피소드

Artwork
icon공유
 
Manage episode 282696802 series 1464352
Dr Neil Love에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Dr Neil Love 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Featuring an interview with Dr Shannon N Westin on the following topics:

  • Evolving role of PARP inhibition in the management of ovarian cancer (OC) (0:00)
  • Frequency and clinical significance of germline and somatic BRCA mutations and other genomic signatures that may predict benefit from PARP inhibition (3:46)
  • Pivotal Phase III trials of PARP inhibitors alone or in combination with bevacizumab as maintenance therapy for patients with newly diagnosed OC (8:51)
  • Approaches to overcoming PARP inhibitor resistance; PARP inhibitors in combination with immune checkpoint inhibitors (17:56)
  • Novel immune checkpoint inhibitor-based regimens under investigation in OC (25:15)
  • Case: A woman in her early 40s with newly diagnosed high-grade serous OC with a somatic BRCA mutation (28:03)
  • Integration of maintenance PARP inhibition alone or in combination with bevacizumab into the management of newly diagnosed OC (33:32)
  • Duration of PARP inhibitor maintenance therapy; clinical management of common treatment-associated side effects (38:19)
  • Case: A woman in her mid-60s with newly diagnosed Stage IV high-grade serous OC with evidence of genomic instability on her homologous recombination deficiency test (43:09)
  • Activity and tolerability of olaparib/bevacizumab as maintenance therapy (51:14)
  • Case: A woman in her early 50s with newly diagnosed Stage IV homologous recombination-proficient OC (58:53)

CME information and select publications

  continue reading

1296 에피소드

All episodes

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드